Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 21Triple Negative Breast Neoplasms 12Inflammatory Breast Neoplasms 2Carcinoma, Adenoid Cystic 2Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Hodgkin Disease 1HR+/HER2- Breast Cancer 1Epstein-Barr Virus Infections 1Down Syndrome 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

Rituximab 45Cyclophosphamide 32Lenalidomide 24fludarabine 20zanubrutinib 13venetoclax 12obinutuzumab 12orelabrutinib 11fludarabine phosphate 10Bendamustine Hydrochloride 10Magnetic Resonance Spectroscopy 9Whole-Body Irradiation 8Prednisone 8pirtobrutinib 7ibrutinib 7Vincristine 7Specimen Handling 7CT-P10 7Mycophenolic Acid 6Biopsy 6Doxorubicin 5tafasitamab 4pembrolizumab 3acalabrutinib 3Tacrolimus 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × Epirubicin × 1 year × Clear all
NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Henan Cancer Hospital

Phase 2 Completed
26 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡